**Appendix Table E38. Results from studies assessing the ability of VerifyNow to predict stroke in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Breet, 2010{Breet, 2010 86 /id}20179285NetherlandsPOPULAR | maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily | VerifyNow P2Y12 | stroke  | Stroke  | 1-year  | High OTPR | Stroke  | 7/406(1.7) | OR=1.87 | 0.62-5.61 | <0.26 | No  | NR |  |
|  |  |  |  |  |  | Normal OTPR |  | 6/646 (0.9) |  |  |  |  |  |  |
| Kim, 2010{Kim, 2010 241 /id}20449634KoreaNR | 300-600mg LD and 75 mg maintain dose clopidogrel  | VerifyNow P2Y12 (PRU) | ischemic stroke  | ischemic stroke  | 6 months |  <240 | ischemic stroke  | 0% | OR=1.0 | 0.99-1.01 | 0.524 | NR | NR |  |
|  |  |  |  |  |  | ≥240 |  | 0.3% |  |  |  |  |  |  |
| Campo, 2010{Campo, 2010 58 /id}2095132010 sites in Italy, Belgium, France, Sprain3T/2R trial | Clopidogrel LD 300 or 600 mg or maintaining 75mg daily | VerifyNowP2Y12 | Stroke  | Stroke  | 1-year | Full responder | Stroke  | 0/289 (0) | NR | NR | 0.2 | NR | NR |  |
|  |  |  |  |  |  | Poor responder |  | 2/179 (1.1) |  |  |  |  |  |  |
| Kim, 2011{Kim, 2011 5 /id}21786434South KoreaCiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial) | Clopidogrel+aspirin | VerifyNow | Cerebrovascular accident |  | 6 months | Clopidogrel resistance |  | 1/37 (1%) |  |  | NS vs. next row (chi-square statistics or Fisher ’s exact test) |  |  |  |
|  |  |  |  |  |  | Normal response |  | 0/73 (0%) |  |  |  |  |  |  |
| Breet, 2011{Breet, 2011 15 /id}21478385The NetherlandsPOPular | Clopidogrel LD 300 or 600mg or maintaining 75 mg daily | VerifyNow | Stroke  | Stroke  | 1 year | HCPR(high on-clopidogrel platelet reactivity) or dual HPR | Stroke  | 3/168 | NR | NR | NR | NR | NR |  |
| Park, 2011 {Park, 2011 1 /id} 22152948KoreaNR | clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/dayaspirin LD 200mg, MD 100-200 mg/day | VeryfyNow | stroke |  stroke | 2-year | HTPR (PRU >235 and/or a % inhibition <15%) | stroke | high 17/1660(0.9) | HR=1.54 | 0.68-3.47 | 0.30comparing with normal cox proportional model  | NR | NR |  |
|  |  |  |  |  |  |  |  | normal9/1189(0.7) |  |  |  |  |  |  |
| Jin, 2012 {Jin, 2012 18230 /id} KoreaNR | 600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD | VerifyNow P2Y12 | ischemic stroke | ischemic stroke | 12 months | no HPR  | ischemic stroke | 1/127=1.0% | HR=2 | 0.12-32.32 | 0.627 comparing with HPRcox-model | **yes** | **No** |  |
|  |  |  |  |  |  | HPR |  ischemic stroke | 1/54=1.9% |  |  |  |  |  |  |
| Yu, 2012 {Yu, 2012 18231 /id}22787468KoreaNR | LD 300mg aspirin and 300 mg clopidogrel, | VerifyNow P2Y12 | stroke | stroke | 12 months | respondern=109 | stroke | 3/109=2.6% | OR=2.15(calculated) | 0.22-21.08) | 0.519 comparing with low responderchi square test or Fisher’s exact test | **No** | **No** | **no** |
|  |  |  |  |  |  | low responder n=77 |  | 1/77=1.3% |  |  |  |  |  |  |